Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT-1161 (Oteseconazole) for Recurrent Vulvovaginal Candidiasis
NCT02267382Phase 2Completed
- Sponsor
- Viamet Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oteseconazole in recurrent vulvovaginal candidiasis (RVVC), sponsored by Viamet Pharmaceuticals. Started Feb 2015; status: completed.
02
Drugs
oteseconazole
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on NCT02267382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267382.